Q-omics provides the consensus-scored PROK1 profile across patient tissues and cancer cell-line models. PROK1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PROK1 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, PROK1 RNA expression shows 10,016 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, and ESCA as cancer lineages where PROK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROK1 survival associations across molecular data types. PROK1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROK1 RNA expression–survival associations across cancer types. High PROK1 expression shows unfavorable associations in KICH and LGG, but favorable associations in PAAD, LIHC, PRAD and SARC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PROK1 RNA expression.
This table summarizes PROK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PROK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROK1 shows lower tumor expression in KICH, BRCA, KIRC, PRAD, KIRP and LUSC. The KICH box plot shows higher PROK1 RNA expression in normal versus tumor tissue (log2 FC = −0.301, t-test p < 0.001).
This table shows molecular features associated with PROK1 in patient tissues and cancer cell lines. In patient samples, PROK1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PROK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and PANCREAS.
